DUBLIN – 4Teen4 Pharmaceuticals GmbH raised €6.9 million (US$7.7 million) in a series A round to take procizumab, a first-in-class inhibitor of circulating dipeptidyl-peptidase 3 (cDPP3), into clinical trials for patients with cardiogenic shock.
Civetta Therapeutics LLC will take a $53 million series A to advance its platform and programs based on beta-propeller proteins that mediate protein-to-protein interactions. Those proteins can become involved in cancers, neurodegeneration and metabolic disorders, with oncology being the company’s initial focus.
DUBLIN – Imcheck Therapeutics SAS raised €48 million (US$53.2 million) in a series B financing round to move a pipeline of antibodies targeting gamma delta T cells into the clinic.
BEIJING – Chengdu-based Sichuan Clover Biopharmaceuticals Inc. closed a series B financing round to inject another $43 million into its drug development and manufacturing operations, with a focus on biologic candidate SCB-313, developed with its Trimer-Tag technology platform.
With a 349% increase in stock price since its June debut on U.S. markets, Boston-based Karuna Therapeutics Inc. secures the title of best IPO performer so far in 2019. The stock skyrocketed in November following positive top-line phase II data of Karxt in acute psychosis in patients with schizophrenia, providing a potential read-through to larger indications such as Alzheimer’s disease and pain.
PERTH, Australia – On the heels of positive phase IIb data, Melbourne-based Opthea Ltd. announced a private placement of AU$50 million (US$33.87 million) from institutional investors in Australia and the U.K. to advance lead candidate OPT-302 to phase III trials in wet age-related macular degeneration (AMD).
IFM Therapeutics LLC, an innate immunity specialist that's quickly sparked major deals with big pharma, is stoking the generative fire at its heart with $55.5 million in new financing led by Boston-based Omega Funds. The Boston-based company will use the funds to launch as many as three new subsidiaries, starting with IFM Quattro and a new incubator, IFM Discovery.
RSS
